Literature DB >> 27664320

The effect of time changes in diagnosing lung cancer type on its recorded distribution, with particular reference to adenocarcinoma.

Peter N Lee1, John R Gosney2.   

Abstract

Among lung cancers, a substantial shift over time has occurred in the recorded frequency of adenocarcinoma (AdC) relative to that of squamous cell carcinoma (SqCC). This is evident in many countries, and also in those who have never smoked. We attempted to address the extent to which this increase is real, or an artefact of changing diagnostic practices. We reviewed studies re-evaluating diagnoses using more up-to-date criteria, and studies applying standard criteria to cases collected over a long period. We also describe changes to classifications, and factors affecting diagnostic accuracy and consistency. While the four main types have long remained essentially unchanged, successive WHO classifications differ in how tumours are ascribed to these types. Despite refinement of classifications and technological advances, the decision is ultimately the pathologist's. In 11 studies, 189/1212(15.6%) originally diagnosed AdCs were reclassified as non-AdC on review, whereas 541/1564(34.6%) of non-AdCs were reclassified as AdC, increasing AdCs by 30%. Studies examining trends in the proportion of AdC were conflicting; three showing a declining trend, seven no trend, and six some increase. Some studies find lepidic (bronchioloalveolar) carcinoma, but not other AdC sub-types, increased. The rising AdC/SqCC ratio results at least partly from diagnostic changes. Copyright Â
© 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diagnostic accuracy; Histological type; Lung cancer; Time trends

Mesh:

Year:  2016        PMID: 27664320     DOI: 10.1016/j.yrtph.2016.09.019

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  1 in total

1.  Reversal effect of adenovirus-mediated human interleukin 24 transfection on the cisplatin resistance of A549/DDP lung cancer cells.

Authors:  Mingju Xu; Xioawei Tang; Jinjin Guo; Wangbang Sun; Faqing Tang
Journal:  Oncol Rep       Date:  2017-09-26       Impact factor: 3.906

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.